Document is current

Article History

Received: 18 June 2025

Accepted: 5 February 2026

First Online: 27 February 2026

Declarations

:

: The study protocol was approved by the Cedars-Sinai Institutional Review Board.

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study. The study protocol was approved by the Cedars-Sinai Institutional Review Board.

: Although improvement in cardiac function is typical over the course of weeks after a Takotsubo syndrome event, adverse outcomes after apparent recovery are now recognized. The pathophysiology of these longer-term manifestations remains poorly defined. We demonstrate a distinct blood proteome in Takotsubo syndrome survivors compared with reference controls. This work supports a chronic heart failure phenotype after a Takotsubo syndrome event, and underscores the importance of long-term monitoring and treatment of these patients.

: Dr. Bairey Merz holds stock in iRhythm and serves on the Board of Directors. The remaining authors have no conflicts to disclose.

: NCT03910569.